Back to results
US 4,283,539 AGranted
Isoquinoline acetic acids
AssigneePfizer Inc.
InventorRodney C. Schnur
Life of this patent
Estimating the term…
Abstract
Novel isoquinoline acetic acids and derivatives thereof useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications, especially diabetic cataracts are disclosed. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of treatment of diabetic cataracts by administration of effective amounts of the novel compounds described herein.
Claims13
A compound selected from the group consisting of those of the formulae ##STR4## wherein R is selected from the group consisting of hydrogen and alkyl of 1 to 3 carbon atoms;
- R.sub.1 is selected from the group consisting of --CH.sub.2 --X and --O--CH.sub.2 --X;
- R.sub.2 is --CH.sub.2 --X;
- R.sub.3 is selected from the group consisting of --X and --CH.sub.2 --X;
- and R.sub.4 is selected from hydrogen and methyl;
- wherein X is selected from the group consisting of phenyl, monosubstituted and disubstituted phenyl, said substituents being selected from the group consisting of chloro, bromo and fluoro;
- and the pharmaceutically-acceptable salts thereof.
3 more elements
Dependencies are inferred from the claim text.